Extracorporeal Photopheresis as a Treatment for Patients with Cutaneous T-Cell Lymphoma: Real-World Data at a Reference Cancer Center in Colombia.

La fotoféresis extracorpórea (FEC) es una terapia innovadora, con beneficio clínico y baja toxicidad para pacientes con linfomas cutáneos de células T (CTCL) en estadios avanzados. La FEC Está disponible en el Instituto Nacional de Cancerología en Bogotá, Colombia desde 2016, siendo el único disposi...

Full description

Autores:: Toquica, Alejandra
Enciso, Leonardo
Rueda, Xavier
Diaz, Martha

Tipo de recurso:: Trabajo de grado de pregrado

Fecha de publicación:: 2019

Institución:: Universidad Militar Nueva Granada

Repositorio:: Repositorio UMNG

Idioma:: spa

id	UNIMILTAR2_ede64d2fb7266208e0f196a07ad966b8
oai_identifier_str	oai:repository.unimilitar.edu.co:10654/37417
network_acronym_str	UNIMILTAR2
network_name_str	Repositorio UMNG
repository_id_str
dc.title.spa.fl_str_mv	Extracorporeal Photopheresis as a Treatment for Patients with Cutaneous T-Cell Lymphoma: Real-World Data at a Reference Cancer Center in Colombia.
dc.title.translated.spa.fl_str_mv	Extracorporeal photopheresis as a treatment for patients with cutaneous T-Cell Lymphoma: Real-World Data at a Reference cáncer center in Colombia.
title	Extracorporeal Photopheresis as a Treatment for Patients with Cutaneous T-Cell Lymphoma: Real-World Data at a Reference Cancer Center in Colombia.
spellingShingle	Extracorporeal Photopheresis as a Treatment for Patients with Cutaneous T-Cell Lymphoma: Real-World Data at a Reference Cancer Center in Colombia. Cutaneous T-cell lymphoma Mycosis fungoides Sésary syndrome Extracorporeal photopheresis Real-world use Neoplasias Cutáneas Linfoma Cutáneo Fotoféresis Linfoma Cutáneo de Células T Cutaneous T-cell lymphoma Mycosis fungoides Sésary syndrome Extracorporeal photopheresis Real-world use
title_short	Extracorporeal Photopheresis as a Treatment for Patients with Cutaneous T-Cell Lymphoma: Real-World Data at a Reference Cancer Center in Colombia.
title_full	Extracorporeal Photopheresis as a Treatment for Patients with Cutaneous T-Cell Lymphoma: Real-World Data at a Reference Cancer Center in Colombia.
title_fullStr	Extracorporeal Photopheresis as a Treatment for Patients with Cutaneous T-Cell Lymphoma: Real-World Data at a Reference Cancer Center in Colombia.
title_full_unstemmed	Extracorporeal Photopheresis as a Treatment for Patients with Cutaneous T-Cell Lymphoma: Real-World Data at a Reference Cancer Center in Colombia.
title_sort	Extracorporeal Photopheresis as a Treatment for Patients with Cutaneous T-Cell Lymphoma: Real-World Data at a Reference Cancer Center in Colombia.
dc.creator.fl_str_mv	Toquica, Alejandra Enciso, Leonardo Rueda, Xavier Diaz, Martha
dc.contributor.advisor.none.fl_str_mv	Enciso, Leonardo
dc.contributor.author.none.fl_str_mv	Toquica, Alejandra Enciso, Leonardo Rueda, Xavier Diaz, Martha
dc.subject.keywords.spa.fl_str_mv	Cutaneous T-cell lymphoma Mycosis fungoides Sésary syndrome Extracorporeal photopheresis Real-world use
topic	Cutaneous T-cell lymphoma Mycosis fungoides Sésary syndrome Extracorporeal photopheresis Real-world use Neoplasias Cutáneas Linfoma Cutáneo Fotoféresis Linfoma Cutáneo de Células T Cutaneous T-cell lymphoma Mycosis fungoides Sésary syndrome Extracorporeal photopheresis Real-world use
dc.subject.decs.spa.fl_str_mv	Neoplasias Cutáneas Linfoma Cutáneo Fotoféresis Linfoma Cutáneo de Células T
dc.subject.proposal.spa.fl_str_mv	Cutaneous T-cell lymphoma Mycosis fungoides Sésary syndrome Extracorporeal photopheresis Real-world use
description	La fotoféresis extracorpórea (FEC) es una terapia innovadora, con beneficio clínico y baja toxicidad para pacientes con linfomas cutáneos de células T (CTCL) en estadios avanzados. La FEC Está disponible en el Instituto Nacional de Cancerología en Bogotá, Colombia desde 2016, siendo el único dispositivo en el país. El objetivo de este estudio es generar evidencia del mundo real, describiendo los resultados de los pacientes tratados con FEC mediante un análisis descriptivo de las características de la población, los resultados del tratamiento en términos de respuesta y supervivencia, y las complicaciones asociadas. Se trata de un estudio descriptivo de serie de casos, que incluyó a pacientes diagnosticados de MF y SS eritrodérmicos, tratados con fotoféresis extracorpórea siguiendo protocolos institucionales. Se realizaron 616 sesiones de FEC en 17 pacientes, la tasa de respuesta global (ORR) se obtuvo en dieciséis pacientes (64,7%), con una respuesta parcial (PR) en nueve pacientes (52,9%) y una respuesta completa (CR) en dos pacientes (11,8%). Las tasas de respuesta mejoraron cuando se combinaron con terapias complementarias. La reducción de la mediana mSWAT fue de 98 puntos y la reducción de la mediana de VASP fue de 4 puntos en la escala visual análoga. No se alcanzó la mediana de supervivencia para todo el grupo medida desde el inicio del tratamiento hasta la muerte (IC del 95%: 859-NA). La probabilidad de supervivencia a los 12 meses fue del 82% (IC del 95%: 66-100%). Las complicaciones ocurrieron en el 2% de las sesiones realizadas, la mayoría relacionadas con dificultades en el acceso venoso. La FEC debe considerarse como una terapia de primera línea para la MF / SS eritrodérmica basada no solo en la eficacia y el excelente perfil de efectos secundarios, sino también en la mejora significativa de los síntomas.
publishDate	2019
dc.date.issued.none.fl_str_mv	2019-08-16
dc.date.accessioned.none.fl_str_mv	2021-02-22T16:27:01Z
dc.date.available.none.fl_str_mv	2021-02-22T16:27:01Z
dc.type.local.spa.fl_str_mv	Tesis/Trabajo de grado - Monografía - Especialización
dc.type.driver.spa.fl_str_mv	info:eu-repo/semantics/bachelorThesis
dc.type.coar.*.fl_str_mv	http://purl.org/coar/resource_type/c_7a1f
format	http://purl.org/coar/resource_type/c_7a1f
dc.identifier.uri.none.fl_str_mv	http://hdl.handle.net/10654/37417
dc.identifier.instname.spa.fl_str_mv	instname:Universidad Militar Nueva Granada
dc.identifier.reponame.spa.fl_str_mv	reponame:Repositorio Institucional Universidad Militar Nueva Granada
dc.identifier.repourl.spa.fl_str_mv	repourl:https://repository.unimilitar.edu.co
url	http://hdl.handle.net/10654/37417
identifier_str_mv	instname:Universidad Militar Nueva Granada reponame:Repositorio Institucional Universidad Militar Nueva Granada repourl:https://repository.unimilitar.edu.co
dc.language.iso.spa.fl_str_mv	spa
language	spa
dc.relation.references.spa.fl_str_mv	Edelson, R., et al., Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results. N Engl J Med, 1987. 316(6): p. 297-303. Cho, A., C. Jantschitsch, and R. Knobler, Extracorporeal Photopheresis-An Overview. Front Med (Lausanne), 2018. 5: p. 236. Perotti, C. and I. Sniecinski, A concise review on extracorporeal photochemotherapy: Where we began and where we are now and where are we going! Transfus Apher Sci, 2015. 52(3): p. 360-8. Phan, A., R. Veldman, and M.J. Lechowicz, T-cell Lymphoma Epidemiology: the Known and Unknown. Curr Hematol Malig Rep, 2016. 11(6): p. 492-503. Willemze, R., et al., The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood, 2019. Korgavkar, K., M. Xiong, and M. Weinstock, Changing incidence trends of cutaneous T-cell lymphoma. JAMA Dermatol, 2013. 149(11): p. 1295-9. Olsen, E.A., et al., Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol, 2011. 29(18): p. 2598-607. Imam, M.H., et al., Incidence and survival patterns of cutaneous T-cell lymphomas in the United States. Leuk Lymphoma, 2013. 54(4): p. 752-9. Olsen, E., et al., Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood, 2007. 110(6): p. 1713-22. Agar, N.S., et al., Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol, 2010. 28(31): p. 4730-9. Jawed, S.I., et al., Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions. J Am Acad Dermatol, 2014. 70(2): p. 223.e1-17; quiz 240-2. Photiou, L., et al., Systemic Treatment Options for Advanced-Stage Mycosis Fungoides and Sézary Syndrome. Curr Oncol Rep, 2018. 20(4): p. 32. Trautinger, F., et al., European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2017. Eur J Cancer, 2017. 77: p. 57-74. Hughes, C.F., et al., Lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: a comparative study of systemic therapy. Blood, 2015. 125(1): p. 71-81. Wilcox, R.A., Cutaneous T-cell lymphoma: 2017 update on diagnosis, risk-stratification, and management. Am J Hematol, 2017. 92(10): p. 1085-1102. Zic, J.A., The treatment of cutaneous T-cell lymphoma with photopheresis. Dermatol Ther, 2003. 16(4): p. 337-46. Larocca, C. and T. Kupper, Mycosis Fungoides and Sézary Syndrome: An Update. Hematol Oncol Clin North Am, 2019. 33(1): p. 103-120. Quaglino, P., et al., Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium. Ann Oncol, 2017. 28(10): p. 2517-2525. Zic, J.A., Extracorporeal Photopheresis in the Treatment of Mycosis Fungoides and Sézary Syndrome. Dermatol Clin, 2015. 33(4): p. 765-76. Ling, Y.L., et al., Real-world use of extracorporeal photopheresis for patients with cutaneous T-cell lymphoma in the United States: 2010-2015. J Dermatolog Treat, 2020. 31(1): p. 91-98. McKenna, K.E., et al., Evidence-based practice of photopheresis 1987-2001: a report of a workshop of the British Photodermatology Group and the U.K. Skin Lymphoma Group. Br J Dermatol, 2006. 154(1): p. 7-20. Ratcliffe, N., et al., National Institutes of Health State of the Science Symposium in Therapeutic Apheresis: scientific opportunities in extracorporeal photopheresis. Transfus Med Rev, 2015. 29(1): p. 62-70. NCCN Clinical Practice Guidelines in Oncology. Primary Cutaneous Lymphomas. Version 1.2021. October, 2020: https://www.nccn.org/professionals/physician_gls/default.aspx. Gilson, D., et al., British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous lymphomas 2018. Br J Dermatol, 2019. 180(3): p. 496-526. Papa, G., et al., Is interferon alpha in cutaneous T-cell lymphoma a treatment of choice? Br J Haematol, 1991. 79 Suppl 1: p. 48-51. Aviles, A., et al., Interferon and low doses of methotrexate versus interferon and retinoids in the treatment of refractory/relapsed cutaneous T-cell lymphoma. Hematology, 2015. 20(9): p. 538-42. Scarisbrick, J.J., et al., U.K. consensus statement on the use of extracorporeal photopheresis for treatment of cutaneous T-cell lymphoma and chronic graft-versus-host disease. Br J Dermatol, 2008. 158(4): p. 659-78. Duvic, M., N. Chiao, and R. Talpur, Extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma. J Cutan Med Surg, 2003. 7(4 Suppl): p. 3-7. Raphael, B.A., et al., High clinical response rate of Sezary syndrome to immunomodulatory therapies: prognostic markers of response. Arch Dermatol, 2011. 147(12): p. 1410-5. Olsen, E.A. and P.A. Bunn, Interferon in the treatment of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am, 1995. 9(5): p. 1089-107. Heald, P., et al., Treatment of erythrodermic cutaneous T-cell lymphoma with extracorporeal photochemotherapy. J Am Acad Dermatol, 1992. 27(3): p. 427-33. Gottlieb, S.L., et al., Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon alfa: a 10-year experience at a single institution. J Am Acad Dermatol, 1996. 35(6): p. 946-57. Zic, J.A., et al., Long-term follow-up of patients with cutaneous T-cell lymphoma treated with extracorporeal photochemotherapy. J Am Acad Dermatol, 1996. 35(6): p. 935-45. Quaglino, P., et al., Extracorporeal photopheresis for the treatment of erythrodermic cutaneous T-cell lymphoma: a single center clinical experience with long-term follow-up data and a brief overview of the literature. Int J Dermatol, 2013. 52(11): p. 1308-18. Bisaccia, E., E.C. Vonderheid, and L. Geskin, Safety of a new, single, integrated, closed photopheresis system in patients with cutaneous T-cell lymphoma. Br J Dermatol, 2009. 161(1): p. 167-9.
dc.rights.uri.*.fl_str_mv	http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights.accessrights.spa.fl_str_mv	info:eu-repo/semantics/openAccess
dc.rights.accessrights.*.fl_str_mv	http://purl.org/coar/access_right/c_abf2
dc.rights.creativecommons.spa.fl_str_mv	Attribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.local.spa.fl_str_mv	Acceso abierto
rights_invalid_str_mv	http://creativecommons.org/licenses/by-nc-nd/4.0/ http://purl.org/coar/access_right/c_abf2 Attribution-NonCommercial-NoDerivatives 4.0 International Acceso abierto
eu_rights_str_mv	openAccess
dc.format.mimetype.spa.fl_str_mv	applicaction/pdf
dc.coverage.spatial.spa.fl_str_mv	Instituto Nacional de Cancerología
dc.coverage.temporal.spa.fl_str_mv	octubre 2016 - Abril 2020
dc.coverage.sede.spa.fl_str_mv	Medicina
dc.publisher.program.spa.fl_str_mv	Dermatología Oncológica
dc.publisher.faculty.spa.fl_str_mv	Facultad de Medicina
dc.publisher.grantor.spa.fl_str_mv	Universidad Militar Nueva Granada
institution	Universidad Militar Nueva Granada
bitstream.url.fl_str_mv	http://repository.unimilitar.edu.co/bitstream/10654/37417/3/Version%20FINAL%20articulo%20FEC-MF.pdf.jpg http://repository.unimilitar.edu.co/bitstream/10654/37417/1/Version%20FINAL%20articulo%20FEC-MF.pdf http://repository.unimilitar.edu.co/bitstream/10654/37417/2/license.txt
bitstream.checksum.fl_str_mv	f09d5f12ddbe4576de90ee1b668d2503 051ed3cc234762f4e3a9970e3e6c762f a609d7e369577f685ce98c66b903b91b
bitstream.checksumAlgorithm.fl_str_mv	MD5 MD5 MD5
repository.name.fl_str_mv	Repositorio Institucional UMNG
repository.mail.fl_str_mv	bibliodigital@unimilitar.edu.co
_version_	1808417963795021824
spelling	Enciso, LeonardoToquica, AlejandraEnciso, LeonardoRueda, XavierDiaz, MarthaEspecialista en Dermatología OncológicaInstituto Nacional de Cancerologíaoctubre 2016 - Abril 2020Medicina2021-02-22T16:27:01Z2021-02-22T16:27:01Z2019-08-16http://hdl.handle.net/10654/37417instname:Universidad Militar Nueva Granadareponame:Repositorio Institucional Universidad Militar Nueva Granadarepourl:https://repository.unimilitar.edu.coLa fotoféresis extracorpórea (FEC) es una terapia innovadora, con beneficio clínico y baja toxicidad para pacientes con linfomas cutáneos de células T (CTCL) en estadios avanzados. La FEC Está disponible en el Instituto Nacional de Cancerología en Bogotá, Colombia desde 2016, siendo el único dispositivo en el país. El objetivo de este estudio es generar evidencia del mundo real, describiendo los resultados de los pacientes tratados con FEC mediante un análisis descriptivo de las características de la población, los resultados del tratamiento en términos de respuesta y supervivencia, y las complicaciones asociadas. Se trata de un estudio descriptivo de serie de casos, que incluyó a pacientes diagnosticados de MF y SS eritrodérmicos, tratados con fotoféresis extracorpórea siguiendo protocolos institucionales. Se realizaron 616 sesiones de FEC en 17 pacientes, la tasa de respuesta global (ORR) se obtuvo en dieciséis pacientes (64,7%), con una respuesta parcial (PR) en nueve pacientes (52,9%) y una respuesta completa (CR) en dos pacientes (11,8%). Las tasas de respuesta mejoraron cuando se combinaron con terapias complementarias. La reducción de la mediana mSWAT fue de 98 puntos y la reducción de la mediana de VASP fue de 4 puntos en la escala visual análoga. No se alcanzó la mediana de supervivencia para todo el grupo medida desde el inicio del tratamiento hasta la muerte (IC del 95%: 859-NA). La probabilidad de supervivencia a los 12 meses fue del 82% (IC del 95%: 66-100%). Las complicaciones ocurrieron en el 2% de las sesiones realizadas, la mayoría relacionadas con dificultades en el acceso venoso. La FEC debe considerarse como una terapia de primera línea para la MF / SS eritrodérmica basada no solo en la eficacia y el excelente perfil de efectos secundarios, sino también en la mejora significativa de los síntomas.Instituto Nacional de CancerologíaBackground: Extracorporeal photopheresis (ECP) is an innovative therapy. It excels in its clinical benefit and low toxicity for patients with cutaneous T-cell lymphomas (CTCL) in advanced stages. ECP is available at the “Instituto Nacional de Cancerología” (National Cancer Institute) in Bogotá, Colombia since 2016. This being currently the only device available in the country. The objective of this study is: to generate real- world evidence by describing the results of patients treated with ECP through a descriptive analysis of population characteristics, showcase the results of the treatment in terms of response and survival, and associated complications regarding said treatment. This is a case-series descriptive study, which included patients diagnosed with erythrodermic MF and SS treated with extracorporeal photopheresis following institutional protocols. Results: 616 ECP sessions were performed in 17 patients. Overall response rate (ORR) was obtained in sixteen patients (64,7%), with a partial response (PR) in nine patients (52,9%), and complete response (CR) in two patients (11.8%). Response rates improved when combined with adjunctive therapies. The median mSWAT reduction was 98 points and the median VASP reduction was 4 points on the analogous visual scale. Median survival for the entire group measured from the onset of treatment until death was not reached (95% CI: 859-NA). The 12-month survival probability was 82% (95% CI: 66-100%). Complications occurred in 2% of performed sessions, most related to difficulties in the venous access. Conclusion: ECP should be considered as first-line therapy for erythrodermic MF/SS based not only on its efficiency and excellent side effect profile but also on the significant improvement of the symptoms.Especializaciónapplicaction/pdfspahttp://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccesshttp://purl.org/coar/access_right/c_abf2Attribution-NonCommercial-NoDerivatives 4.0 InternationalAcceso abiertoExtracorporeal Photopheresis as a Treatment for Patients with Cutaneous T-Cell Lymphoma: Real-World Data at a Reference Cancer Center in Colombia.Extracorporeal photopheresis as a treatment for patients with cutaneous T-Cell Lymphoma: Real-World Data at a Reference cáncer center in Colombia.Tesis/Trabajo de grado - Monografía - Especializacióninfo:eu-repo/semantics/bachelorThesishttp://purl.org/coar/resource_type/c_7a1fCutaneous T-cell lymphomaMycosis fungoidesSésary syndromeExtracorporeal photopheresisReal-world useNeoplasias CutáneasLinfoma CutáneoFotoféresisLinfoma Cutáneo de Células TCutaneous T-cell lymphomaMycosis fungoidesSésary syndromeExtracorporeal photopheresisReal-world useDermatología OncológicaFacultad de MedicinaUniversidad Militar Nueva GranadaEdelson, R., et al., Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results. N Engl J Med, 1987. 316(6): p. 297-303.Cho, A., C. Jantschitsch, and R. Knobler, Extracorporeal Photopheresis-An Overview. Front Med (Lausanne), 2018. 5: p. 236.Perotti, C. and I. Sniecinski, A concise review on extracorporeal photochemotherapy: Where we began and where we are now and where are we going! Transfus Apher Sci, 2015. 52(3): p. 360-8.Phan, A., R. Veldman, and M.J. Lechowicz, T-cell Lymphoma Epidemiology: the Known and Unknown. Curr Hematol Malig Rep, 2016. 11(6): p. 492-503.Willemze, R., et al., The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood, 2019.Korgavkar, K., M. Xiong, and M. Weinstock, Changing incidence trends of cutaneous T-cell lymphoma. JAMA Dermatol, 2013. 149(11): p. 1295-9.Olsen, E.A., et al., Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol, 2011. 29(18): p. 2598-607.Imam, M.H., et al., Incidence and survival patterns of cutaneous T-cell lymphomas in the United States. Leuk Lymphoma, 2013. 54(4): p. 752-9.Olsen, E., et al., Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood, 2007. 110(6): p. 1713-22.Agar, N.S., et al., Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol, 2010. 28(31): p. 4730-9.Jawed, S.I., et al., Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions. J Am Acad Dermatol, 2014. 70(2): p. 223.e1-17; quiz 240-2.Photiou, L., et al., Systemic Treatment Options for Advanced-Stage Mycosis Fungoides and Sézary Syndrome. Curr Oncol Rep, 2018. 20(4): p. 32.Trautinger, F., et al., European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2017. Eur J Cancer, 2017. 77: p. 57-74.Hughes, C.F., et al., Lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: a comparative study of systemic therapy. Blood, 2015. 125(1): p. 71-81.Wilcox, R.A., Cutaneous T-cell lymphoma: 2017 update on diagnosis, risk-stratification, and management. Am J Hematol, 2017. 92(10): p. 1085-1102.Zic, J.A., The treatment of cutaneous T-cell lymphoma with photopheresis. Dermatol Ther, 2003. 16(4): p. 337-46.Larocca, C. and T. Kupper, Mycosis Fungoides and Sézary Syndrome: An Update. Hematol Oncol Clin North Am, 2019. 33(1): p. 103-120.Quaglino, P., et al., Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium. Ann Oncol, 2017. 28(10): p. 2517-2525.Zic, J.A., Extracorporeal Photopheresis in the Treatment of Mycosis Fungoides and Sézary Syndrome. Dermatol Clin, 2015. 33(4): p. 765-76.Ling, Y.L., et al., Real-world use of extracorporeal photopheresis for patients with cutaneous T-cell lymphoma in the United States: 2010-2015. J Dermatolog Treat, 2020. 31(1): p. 91-98.McKenna, K.E., et al., Evidence-based practice of photopheresis 1987-2001: a report of a workshop of the British Photodermatology Group and the U.K. Skin Lymphoma Group. Br J Dermatol, 2006. 154(1): p. 7-20.Ratcliffe, N., et al., National Institutes of Health State of the Science Symposium in Therapeutic Apheresis: scientific opportunities in extracorporeal photopheresis. Transfus Med Rev, 2015. 29(1): p. 62-70.NCCN Clinical Practice Guidelines in Oncology. Primary Cutaneous Lymphomas. Version 1.2021. October, 2020: https://www.nccn.org/professionals/physician_gls/default.aspx.Gilson, D., et al., British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous lymphomas 2018. Br J Dermatol, 2019. 180(3): p. 496-526.Papa, G., et al., Is interferon alpha in cutaneous T-cell lymphoma a treatment of choice? Br J Haematol, 1991. 79 Suppl 1: p. 48-51.Aviles, A., et al., Interferon and low doses of methotrexate versus interferon and retinoids in the treatment of refractory/relapsed cutaneous T-cell lymphoma. Hematology, 2015. 20(9): p. 538-42.Scarisbrick, J.J., et al., U.K. consensus statement on the use of extracorporeal photopheresis for treatment of cutaneous T-cell lymphoma and chronic graft-versus-host disease. Br J Dermatol, 2008. 158(4): p. 659-78.Duvic, M., N. Chiao, and R. Talpur, Extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma. J Cutan Med Surg, 2003. 7(4 Suppl): p. 3-7.Raphael, B.A., et al., High clinical response rate of Sezary syndrome to immunomodulatory therapies: prognostic markers of response. Arch Dermatol, 2011. 147(12): p. 1410-5.Olsen, E.A. and P.A. Bunn, Interferon in the treatment of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am, 1995. 9(5): p. 1089-107.Heald, P., et al., Treatment of erythrodermic cutaneous T-cell lymphoma with extracorporeal photochemotherapy. J Am Acad Dermatol, 1992. 27(3): p. 427-33.Gottlieb, S.L., et al., Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon alfa: a 10-year experience at a single institution. J Am Acad Dermatol, 1996. 35(6): p. 946-57.Zic, J.A., et al., Long-term follow-up of patients with cutaneous T-cell lymphoma treated with extracorporeal photochemotherapy. J Am Acad Dermatol, 1996. 35(6): p. 935-45.Quaglino, P., et al., Extracorporeal photopheresis for the treatment of erythrodermic cutaneous T-cell lymphoma: a single center clinical experience with long-term follow-up data and a brief overview of the literature. Int J Dermatol, 2013. 52(11): p. 1308-18.Bisaccia, E., E.C. Vonderheid, and L. Geskin, Safety of a new, single, integrated, closed photopheresis system in patients with cutaneous T-cell lymphoma. Br J Dermatol, 2009. 161(1): p. 167-9.THUMBNAILVersion FINAL articulo FEC-MF.pdf.jpgVersion FINAL articulo FEC-MF.pdf.jpgIM Thumbnailimage/jpeg8922http://repository.unimilitar.edu.co/bitstream/10654/37417/3/Version%20FINAL%20articulo%20FEC-MF.pdf.jpgf09d5f12ddbe4576de90ee1b668d2503MD53ORIGINALVersion FINAL articulo FEC-MF.pdfVersion FINAL articulo FEC-MF.pdfarticulo original, en proceso de publicacionapplication/pdf1115068http://repository.unimilitar.edu.co/bitstream/10654/37417/1/Version%20FINAL%20articulo%20FEC-MF.pdf051ed3cc234762f4e3a9970e3e6c762fMD51LICENSElicense.txtlicense.txttext/plain; charset=utf-83420http://repository.unimilitar.edu.co/bitstream/10654/37417/2/license.txta609d7e369577f685ce98c66b903b91bMD5210654/37417oai:repository.unimilitar.edu.co:10654/374172021-02-23 01:03:50.092Repositorio Institucional UMNGbibliodigital@unimilitar.edu.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

Extracorporeal Photopheresis as a Treatment for Patients with Cutaneous T-Cell Lymphoma: Real-World Data at a Reference Cancer Center in Colombia.

Publicaciones similares